Korean Drug고려제약
014570 · KOSDAQ · ₩014570 · 고려제약
₩2,810▼ ₩30 (1.06%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 44.0% | 42.6% | 47.1% | 45.9% | 43.2% | 41.7% |
| Operating margin | 11.8% | 11.1% | 12.5% | 22.2% | 17.9% | 15.1% |
| Net margin | 1.7% | 10.4% | 4.1% | −6.0% | 14.8% | 12.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +4.6% | −14.4% | −10.3% | +1.7% | +7.4% | — |
| Operating income growth | +11.4% | −24.4% | −49.3% | +25.8% | +27.2% | — |
| Net income growth | −83.4% | +117.4% | +160.9% | −141.6% | +30.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 1.3% | 8.1% | 3.9% | −6.1% | 14.6% | 11.8% |
| Return on assets | 1.1% | 7.1% | 3.4% | −5.3% | 12.9% | 10.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 25.5% | 13.5% | 13.8% | 16.4% | 11.6% | 15.5% |
| Net debt to equity | — | — | — | — | — | — |
| Current ratio | 438.5% | 833.0% | 872.7% | 640.5% | 979.8% | 682.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Korean Drug / 고려제약 / 014570 / KRX:014570
Source: KRX statistical information